Clene Nanomedicine Raises Series D Financing of $42.5 Million

SALT LAKE CITY, Aug. 26, 2020 -- (Healthcare Sales & Marketing Network) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it has secured $42.5 million in a Series D financing. The round was led by SymBiosis II, ... Biopharmaceuticals, Neurology, Venture Capital Clene Nanomedicine, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news